US › Healthcare

Cue Biopharma (CUE)

US · Healthcare · Biotechnology

$18.73+4.00%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$7.9M

Revenue YoY

+166.7%

Net profit

$-153.1M

EPS

$-13.81

EPS estimate

$-1.69

Net margin

-1,943.2%

EPS came in at -13.81 against a street estimate of -1.69 — a miss of 717.2%.

Key statistics

Market cap

$136.1M

Forward P/E

0.0

P/B

56.68

Book value

$0.44

EPS (TTM)

$-29.59

52-week high

$45.50

52-week low

$4.97

50-day MA

$25.03

200-day MA

$21.35

Beta

2.81

Analyst view

Analysts rate Cue Biopharma a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $88.00.

Shareholding

Insiders

15.05%

Institutions

22.70%

Largest institutional holders

Fund	Stake
Bleichroeder LP	5.10%
Driehaus Capital Management LLC	4.02%
Vanguard Capital Management, LLC	2.23%
Ikarian Capital, LLC	1.44%
Polygon Management Ltd	1.29%
StemPoint Capital LP	0.92%
BlackRock Inc	0.80%
ADAR1 Capital Management LLC	0.76%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cue Biopharma — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.